Summary
The amount of fibrinolytic activity in the thyroid gland equals that of the prostate. In order to examine the effect of the antifibrinolytic drug tranexemic acid on perioperative bleeding saline or tranexemic acid were given randomized double blind to 76 consecutive patients who came for scheduled thyroid surgery. No significant differences were found in perioperative bleeding between patients in the treatment group (n=39) and control group (n=37).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Albrechtsen OK (1959) Fibrinolytic activity in the organism. Acta Physiol Scand 47 [suppl 165]:36
Biggs JC, Hugh TB, Dodds AJ (1976) Tranexamic acid and upper gastrointestinal hemorrhage — a double-blind trial. Gut 17:729–374
Bramsen T (1976) Traumatic hyphaema treated with the antifibrinolytic drug tranexamic acid. Acta Ophthalm 54:250–256
Hedlund PO (1969) Antifibrinolytic therapy with Cyklokapron in connection with prostatectomy. Scand J Urol Nephrol 3:177–182
Nilsson L, Rybo G (1967) Treatment of menorrhagia with an antifibrinolytic agent, tranexemic acid (AMCA). A double-blind investigation. Acta Obstet Gynccol Scand 46:572–580
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Auvinen, O., Baer, G.A., Nordback, I. et al. Antifibrinolytic therapy for prevention of hemorrhage during surgery of the thyroid gland. Klin Wochenschr 65, 253–255 (1987). https://doi.org/10.1007/BF01773442
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01773442